294 related articles for article (PubMed ID: 26686637)
1. Wallerian Degeneration Is Executed by an NMN-SARM1-Dependent Late Ca(2+) Influx but Only Modestly Influenced by Mitochondria.
Loreto A; Di Stefano M; Gering M; Conforti L
Cell Rep; 2015 Dec; 13(11):2539-2552. PubMed ID: 26686637
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration.
Loreto A; Hill CS; Hewitt VL; Orsomando G; Angeletti C; Gilley J; Lucci C; Sanchez-Martinez A; Whitworth AJ; Conforti L; Dajas-Bailador F; Coleman MP
Neurobiol Dis; 2020 Feb; 134():104678. PubMed ID: 31740269
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection.
Sasaki Y; Zhu J; Shi Y; Gu W; Kobe B; Ve T; DiAntonio A; Milbrandt J
Exp Neurol; 2021 Nov; 345():113842. PubMed ID: 34403688
[TBL] [Abstract][Full Text] [Related]
4. SARM1 is a metabolic sensor activated by an increased NMN/NAD
Figley MD; Gu W; Nanson JD; Shi Y; Sasaki Y; Cunnea K; Malde AK; Jia X; Luo Z; Saikot FK; Mosaiab T; Masic V; Holt S; Hartley-Tassell L; McGuinness HY; Manik MK; Bosanac T; Landsberg MJ; Kerry PS; Mobli M; Hughes RO; Milbrandt J; Kobe B; DiAntonio A; Ve T
Neuron; 2021 Apr; 109(7):1118-1136.e11. PubMed ID: 33657413
[TBL] [Abstract][Full Text] [Related]
5. Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons.
Alexandris AS; Ryu J; Rajbhandari L; Harlan R; McKenney J; Wang Y; Aja S; Graham D; Venkatesan A; Koliatsos VE
Neurobiol Dis; 2022 Sep; 171():105808. PubMed ID: 35779777
[TBL] [Abstract][Full Text] [Related]
6. NMN Deamidase Delays Wallerian Degeneration and Rescues Axonal Defects Caused by NMNAT2 Deficiency In Vivo.
Di Stefano M; Loreto A; Orsomando G; Mori V; Zamporlini F; Hulse RP; Webster J; Donaldson LF; Gering M; Raffaelli N; Coleman MP; Gilley J; Conforti L
Curr Biol; 2017 Mar; 27(6):784-794. PubMed ID: 28262487
[TBL] [Abstract][Full Text] [Related]
7. The chemical biology of NAD
Icso JD; Thompson PR
Curr Opin Chem Biol; 2022 Aug; 69():102176. PubMed ID: 35780654
[TBL] [Abstract][Full Text] [Related]
8. Absence of SARM1 rescues development and survival of NMNAT2-deficient axons.
Gilley J; Orsomando G; Nascimento-Ferreira I; Coleman MP
Cell Rep; 2015 Mar; 10(12):1974-81. PubMed ID: 25818290
[TBL] [Abstract][Full Text] [Related]
9. Sarm1 Deletion, but Not Wld
Gilley J; Ribchester RR; Coleman MP
Cell Rep; 2017 Oct; 21(1):10-16. PubMed ID: 28978465
[TBL] [Abstract][Full Text] [Related]
10. Wallerian degeneration: an emerging axon death pathway linking injury and disease.
Conforti L; Gilley J; Coleman MP
Nat Rev Neurosci; 2014 Jun; 15(6):394-409. PubMed ID: 24840802
[TBL] [Abstract][Full Text] [Related]
11. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD
Sasaki Y; Nakagawa T; Mao X; DiAntonio A; Milbrandt J
Elife; 2016 Oct; 5():. PubMed ID: 27735788
[TBL] [Abstract][Full Text] [Related]
12. The NAD
Llobet Rosell A; Paglione M; Gilley J; Kocia M; Perillo G; Gasparrini M; Cialabrini L; Raffaelli N; Angeletti C; Orsomando G; Wu PH; Coleman MP; Loreto A; Neukomm LJ
Elife; 2022 Dec; 11():. PubMed ID: 36476387
[TBL] [Abstract][Full Text] [Related]
13. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.
Geisler S; Doan RA; Cheng GC; Cetinkaya-Fisgin A; Huang SX; Höke A; Milbrandt J; DiAntonio A
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484833
[TBL] [Abstract][Full Text] [Related]
14. Sarm1 haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration.
Gould SA; Gilley J; Ling K; Jafar-Nejad P; Rigo F; Coleman M
Cell Rep; 2021 Dec; 37(11):110108. PubMed ID: 34910914
[TBL] [Abstract][Full Text] [Related]
15. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration.
Di Stefano M; Nascimento-Ferreira I; Orsomando G; Mori V; Gilley J; Brown R; Janeckova L; Vargas ME; Worrell LA; Loreto A; Tickle J; Patrick J; Webster JR; Marangoni M; Carpi FM; Pucciarelli S; Rossi F; Meng W; Sagasti A; Ribchester RR; Magni G; Coleman MP; Conforti L
Cell Death Differ; 2015 May; 22(5):731-42. PubMed ID: 25323584
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.
Bosanac T; Hughes RO; Engber T; Devraj R; Brearley A; Danker K; Young K; Kopatz J; Hermann M; Berthemy A; Boyce S; Bentley J; Krauss R
Brain; 2021 Nov; 144(10):3226-3238. PubMed ID: 33964142
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxins subvert the allosteric activation mechanism of SARM1 to induce neuronal loss.
Wu T; Zhu J; Strickland A; Ko KW; Sasaki Y; Dingwall CB; Yamada Y; Figley MD; Mao X; Neiner A; Bloom AJ; DiAntonio A; Milbrandt J
Cell Rep; 2021 Oct; 37(3):109872. PubMed ID: 34686345
[TBL] [Abstract][Full Text] [Related]
18. SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.
Gerdts J; Brace EJ; Sasaki Y; DiAntonio A; Milbrandt J
Science; 2015 Apr; 348(6233):453-7. PubMed ID: 25908823
[TBL] [Abstract][Full Text] [Related]
19. The SARM1 axon degeneration pathway: control of the NAD
Figley MD; DiAntonio A
Curr Opin Neurobiol; 2020 Aug; 63():59-66. PubMed ID: 32311648
[TBL] [Abstract][Full Text] [Related]
20. Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1.
Henninger N; Bouley J; Sikoglu EM; An J; Moore CM; King JA; Bowser R; Freeman MR; Brown RH
Brain; 2016 Apr; 139(Pt 4):1094-105. PubMed ID: 26912636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
